ARK Genomic Revolution ETF (BATS:ARKG) Hits New 12-Month High – Here’s Why

ARK Genomic Revolution ETF (BATS:ARKG) shares reached a new 52-week high on Tuesday. The company traded as high as $54.06 and last traded at $53.35, with a volume of 2506679 shares. The stock had previously closed at $53.36.

ARK Genomic Revolution ETF Stock Up 0.5%

The business’s 50 day moving average price is $46.15 and its 200-day moving average price is $37.45.

Hedge Funds Weigh In On ARK Genomic Revolution ETF

Hedge funds have recently modified their holdings of the stock. Baird Financial Group Inc. boosted its stake in ARK Genomic Revolution ETF by 0.3% in the 2nd quarter. Baird Financial Group Inc. now owns 73,722 shares of the company’s stock valued at $3,101,000 after buying an additional 255 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in ARK Genomic Revolution ETF by 53.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,088 shares of the company’s stock worth $29,000 after acquiring an additional 378 shares in the last quarter. Rockefeller Capital Management L.P. raised its stake in ARK Genomic Revolution ETF by 1.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 24,243 shares of the company’s stock worth $702,000 after acquiring an additional 461 shares in the last quarter. Summit Investment Advisory Services LLC lifted its holdings in shares of ARK Genomic Revolution ETF by 5.6% during the first quarter. Summit Investment Advisory Services LLC now owns 9,270 shares of the company’s stock valued at $245,000 after acquiring an additional 495 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in shares of ARK Genomic Revolution ETF by 2.9% during the first quarter. Private Advisor Group LLC now owns 21,144 shares of the company’s stock valued at $559,000 after acquiring an additional 605 shares during the period.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.